Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin: The JUPITER trial (justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin)

Journal of the American College of Cardiology

Volumn 57, Issue 16, 2011, Pages 1666-1675

  Hsia, Judith ^a,c   MacFadyen, Jean G ^b   Monyak, John ^a   Ridker, Paul M ^b  

^a ASTRAZENECA   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c 1800 Concord Pike PO Box 15437 ^*  (United States)

Author keywords

cardiovascular risk; low density lipoprotein cholesterol; rosuvastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COLON CANCER; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMATURIA; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MORTALITY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; STROKE; UNSTABLE ANGINA PECTORIS;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES;

EID: 79953836812     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.09.082     Document Type: Article

References (38)

1. S.M. Grundy, J.I. Cleeman, and C.N. Bairey Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
2. C. Baigent, A. Keech, and P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
3. S.D. Wiviott, S. Mohanavelu, J.S. Raichlen, V.A. Cain, S.E. Nissen, and P. Libby Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID study) Am J Cardiol 104 2009 29 35
4. M.J. Tikkanen, I. Holme, and N.B. Cater Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus <65 years with coronary heart disease (from the Incremental Decrease Through Aggressive Lipid Lowering [IDEAL] study) Am J Cardiol 103 2009 577 582
5. J.C. LaRosa, S.M. Grundy, and J.J.P. Kastelein Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study) Am J Cardiol 100 2007 747 752 (Pubitemid 47271930)
6. S.D. Wiviott, C.P. Cannon, and D.A. Morrow Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy J Am Coll Cardiol 46 2005 1411 1416 (Pubitemid 41446174)
7. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622 (Pubitemid 28248586)
8. B. Pitt Low-density lipoprotein cholesterol in patients with stable coronary heart diseaseis it time to shift our goals? N Engl J Med 352 2005 1483 1484 (Pubitemid 40471457)
9. M. Tatley, and R. Savage Psychiatric adverse reactions with statins, fibrates and ezetimibe Implications for the use of lipid-lowering agents Drug Safety 30 2007 195 201 (Pubitemid 46425633)
10. A.C. Peltier, and J.W. Russell Advances in understanding drug-induced neuropathies Drug Safety 29 2006 23 30 (Pubitemid 43213893)
11. G. Corrao, A. Zambon, L. Bertu, E. Botteri, O. Leoni, and P. Contiero Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases J Epidemiol Comm Health 58 2004 1047 1051 (Pubitemid 39564208)
12. S. Friis, and J.H. Olsen Statin use and cancer risk: an epidemiologic review Cancer Invest 24 2006 413 424 (Pubitemid 43932687)
13. B.A. Golomb, and M.A. Evans Statin adverse effects A review of the literature and evidence for a mitochondrial mechanism Am J Cardiovasc Drugs 8 2008 383 418
14. L.A. Frassetto, M. Schloetter, M. Mietus-Synder, R.C. Morris Jr., and A. Sebastian Metabolic and physiologic improvements from consuming a paleolithic, hunter-gatherer type diet Eur J Clin Nutr 63 2009 947 955
15. J.H. O'Keefe Jr., and L. Cordain Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer Mayo Clin Proc 79 2004 101 108 (Pubitemid 38018589)
16. M. Abifadel, J.P. Rabs, and M. Devillers Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease Hum Mutat 30 2009 520 529
17. P.M. Ridker, E. Danielson, and F.A.H. Fonseca Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 2009 1175 1182
18. P.M. Ridker, E. Danielson, and F.A.H. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
19. Medical Dictionary for Regulatory Activities http://www.meddramsso.com/ index.asp Accessed March 1, 2011
20. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, D. Roth Modification of Diet in Renal Disease Study Group A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Ann Intern Med 130 1999 461 470 (Pubitemid 29135798)
21. P.S. Sever, B. Dahlof, and N.R. Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial Lancet 361 2003 1149 1158 (Pubitemid 36398384)
22. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
23. H. Nakamura, K. Arakawa, and H. Itakura Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial Lancet 368 2006 1155 1163 (Pubitemid 44444932)
24. J. Shepherd, D.G. Vidt, E. Miller, S. Harris, and J. Blasetto Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program Cardiology 107 2007 433 443 (Pubitemid 46788271)
25. A. Verhulst, P.C. D'Haese, and M.E. De Broe Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells J Am Soc Nephrol 15 2004 2249 2257 (Pubitemid 39159325)
26. S. Ebrahim, J. Sung, Y.M. Song, R.L. Ferrer, D.A. Lawlor, and G. Davey Smith Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study BMJ 333 2006 22 28
27. K. Yano, D.M. Reed, and C.J. MacLean Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program Stroke 20 1989 1460 1465 (Pubitemid 19278129)
28. R.J. Gerson, J.S. MacDonald, and A.W. Alberts On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors Exp Eye Res 50 1990 65 78 (Pubitemid 20058625)
29. M.L. Harris, A.J. Bron, N.A. Brown Oxford Cholesterol Study Group Absence of effect of simvastatin on the progression of lens opacities in a randomized placebo controlled study Br J Ophthalmol 79 1995 996 1002
30. B.E. Klein, R. Klein, K.E. Lee, and L.M. Grady Statin use and incident nuclear cataract JAMA 295 2006 2757 2758
31. R.G. Schlienger, W.E. Haefeli, H. Jick, and C.R. Meier Risk of cataract in patients treated with statins Arch Intern Med 161 2001 2021 2026
32. D. Gaist, L.A. Garcia Rodriguez, C. Huerta, J. Hallas, and S.H. Sindrup Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 56 2001 931 933 (Pubitemid 33788572)
33. M.M. Reidenberg Statins, lack of energy and ubiquinone Br J Clin Pharm 59 2005 606 607
34. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009 (Pubitemid 26338729)
35. J. Shepherd, G.J. Blauw, and M.B. Murphy Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial Lancet 360 2002 163230
36. O. Ben-Yehuda, and A.N. DeMaria Low LDL-C levels and cancer Reassuring but still not definitive J Am Coll Cardiol 52 2008 1150 1151
37. J. Kuoppala, A. Lamminp, and E. Pukkala Statins and cancer: a systematic review and meta-analysis Eur J Cancer 44 2008 2122 2132
38. A.A. Alsheikh-Ali, T.A. Trikalinos, D.M. Kent, and R.H. Karas Statins, low-density lipoprotein cholesterol, and risk of cancer J Am Coll Cardiol 52 2008 1141 1147